High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism

被引:164
作者
Tripodi, A. [1 ]
Legnani, C. [2 ]
Chantarangkul, V. [1 ]
Cosmi, B. [2 ]
Palareti, G. [2 ]
Mannucci, P. M. [1 ]
机构
[1] Univ & IRCCS Maggiore Hosp, Mangiagalli & Regina Elena Fdn, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Dept Internal Med & Med Specialties, I-20122 Milan, Italy
[2] Univ Hosp St Orsola Malpighi, Dept Angiol & Blood Coagulat Marino Golinelli, Bologna, Italy
关键词
endogenous thrombin potential; hypercoagulability; laboratory screening; thrombophilia;
D O I
10.1111/j.1538-7836.2008.03018.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The assessment of the risk of recurrent venous thromboembolism (VTE) is important to determine the optimal duration of secondary prophylaxis. The risk can be estimated by measuring individual parameters reflecting hypercoagulability. Because of the large numbers of such putative parameters, the assessment in individual patients is complex. Application of global assays reflecting the pro-/anti-coagulant balance in vivo would be desirable. Objectives: To investigate the relationship between recurrent VTE and thrombin generation (TG). Patients-methods: Two hundred and fifty-four patients were followed-up after a first episode of unprovoked, objectively documented VTE for a period of 2.7 years after discontinuation of treatment with vitamin K antagonists. TG was measured 1 month after discontinuation of treatment as endogenous thrombin potential (ETP), peak thrombin and lag-time in the presence or absence of thrombomodulin. The study outcome was objectively documented symptomatic recurrent VTE. Results: Patients with ETP or peak (measured in the presence of thrombomodulin) of > 960 nM(*)min or > 193 nM had hazard ratios (HR) (95% CI) for recurrent VTE of 3.41 (1.34-8.68) or 4.57 (1.70-12.2) as compared with those with an ETP < 563 nM(*)min or peak < 115 nM. Patients with lag-time < 14.5 min had HR of 3.19 (1.29-7.89) as compared with those with lag-time > 20.8 min. HR for ETP, peak or lag-time measured in the absence of thrombomodulin were smaller than those measured in the presence of thrombomodulin. Conclusions: The measurement of TG helps to identify patients at higher risk of VTE recurrence. The increased risk may be better appreciated if the test is performed in the presence of thrombomodulin.
引用
收藏
页码:1327 / 1333
页数:7
相关论文
共 34 条
[1]   The thrombogram in rare inherited coagulation disorders:: Its relation to clinical bleeding [J].
Al Dieri, R ;
Peyvandi, F ;
Santagostino, E ;
Giansily, M ;
Mannucci, PM ;
Schved, JF ;
Béguin, S ;
Hemker, HC .
THROMBOSIS AND HAEMOSTASIS, 2002, 88 (04) :576-582
[2]   Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study [J].
Baglin, T ;
Luddington, R ;
Brown, K ;
Baglin, C .
LANCET, 2003, 362 (9383) :523-526
[3]  
Chantarangkul V, 2003, HAEMATOLOGICA, V88, P547
[4]   Thrombophilia, clinical factors, and recurrent venous thrombotic events [J].
Christiansen, SC ;
Cannegieter, SC ;
Koster, T ;
Vandenbroucke, JP ;
Rosendaal, FR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (19) :2352-2361
[5]   Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology [J].
Cushman, M ;
Tsai, AW ;
White, RH ;
Heckbert, SR ;
Rosamond, WD ;
Enright, P ;
Folsom, AR .
AMERICAN JOURNAL OF MEDICINE, 2004, 117 (01) :19-25
[6]   Progress in the understanding of the protein C anticoagulant pathway [J].
Dahlbäck, B .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (02) :109-116
[7]   Are B vitamins a risk factor for venous thromboembolism? Yes [J].
Eichinger, S .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :307-308
[8]   Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism [J].
Eichinger, S .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2003, 33 (5-6) :342-344
[9]   Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism [J].
Eichinger, S ;
Schönauer, V ;
Weltermann, A ;
Minar, E ;
Bialonczyk, C ;
Hirschl, M ;
Schneider, B ;
Quehenberger, P ;
Kyrle, PA .
BLOOD, 2004, 103 (10) :3773-3776
[10]  
Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624